[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-antiphospholipid-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-antiphospholipid-syndrome":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100508736","armenian-nationwide-registry-of-systemic-autoimmune-and-autoinflammatory-diseases-100508736",false,"NCT05904301","Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases","Armenian Nationwide Registry of Systemic Autoimmune and Autoinflammatory Diseases","NAREG","Inclusion Criteria:\n\n1. Patients with a confirmed diagnosis of at least one of following autoimmune systemic diseases:\n\n   Behcet disease, ANCA -positive vasculitis, Takayasu arteritis, Giant cell arteritis, Systemic sclerosis, Sjogren syndrome, Rheumatoid arthritis, Spondylarthritis (psoriatic, ankylosing, crohn's related), Angioedema hereditary and acquired, Pediatric dermatology, Autoinflammatory diseases (hereditary and acquired), Unexplained infertility, Immune thrombocytopenic purpura\u002F Autoimmune hemolytic anemia (ITP, AHA), Primary anti-phospholipid syndrome (APS), Celiac disease.\n2. Age: major and minor\n3. Patients who have been informed and provided with written informed consent to participate Or consent from legal representative\n\nExclusion Criteria:\n\n1. Patients refusing to participate in the registry\n2. Non-consent from legal representative\n3. Breastfeeding or pregnant patients","ALL",{"count":19,"type":20},800,"ESTIMATED","OBSERVATIONAL","Longitudinal prospective multicenter Armenian registry of systemic autoimmune, autoinflammatory diseases with constitution of bio-banking.",[24,25,26,27,28,29,30,31,32],"Behcet Disease","Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis","Takayasu Arteritis","Giant Cell Arteritis","Sjogren's Syndrome","Rheumatoid Arthritis","Hereditary and Acquired Angioedema","Primary Antiphospholipid Syndrome","Celiac Disease",[34,35,36,37,38,39,40,41,42],"arthritis","autoimmune","systemic","autoinflammatory","Behcet","Takayasu","Giant Cell","Angioedema","APS","RECRUITING","2025-04-04",{"date":46,"type":47},"2025-04-08","ACTUAL",{"date":49,"type":47},"2023-06-21",{"date":51,"type":20},"2028-06-30",{"name":53,"class":54},"Santé Arménie French-Armenian Research Center","OTHER",6,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":72,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100554848","phase-2-the-safety-and-efficiency-of-sirolimus-in-primary-antiphospholipid-syndrome-a-randomized-control-study-100554848","NCT06504420","The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study","A Randomized, Multicenter, Double-blind, Placeobo-control Study of Sirolimus for Primary Antiphospholipid Syndrome Patients","Inclusion Criteria:\n\n1. Understand and sign the informed consent form\n2. Male or Female\n3. aged 18-70 at the time of screening visit\n4. Met 2006 Sapporo classification criteria of APS or 2023 ACR\u002FEULAR classification criteria of APS\n5. With the stable combination therapy\n\nExclusion Criteria:\n\n1. history of serious adverse events or contraindication to Sirolimus\n2. Catastrophic APS within 90 days\n3. Acute thrombosis within 30 days\n4. ≥4\u002F11 American College of Rheumatology Classification Criteria for SLE or other systemic autoimmune diseases\n5. Historically positive HIV test or test positive at screening for HIV\n6. currently on any suppressive therapy for a chronic infection (such as tuberculosis, hepatitis B infection, hepatitis C infection, CMV, EBV, Syphilis, etc)\n7. Surgery treatment within one month\n8. History of malignant neoplasm within the last 5 years\n9. White blood cell counts\\\u003C3×10\\*9\u002FL\n10. Abnormal Liver function tests: ALT or AST ≥ 1.5 times the upper limit of the normal value, and total bilirubin and blood lipids ≥ 2 times the upper limit of the normal value\n11. Pregnant or pregnancy preparation or breastfeed\n12. Any circumstances that may cause the subjects to be unable to complete the study or pose significant risks to the subjects","18 Years","70 Years",{"count":66,"type":20},70,"INTERVENTIONAL",[69],"PHASE2","This study is an Investigator initiated, randomized, multicenter, double-blind, placebo-control study. The aim of this study is to evaluate the safety and efficiency of Sirolimus for primaty antiphospholipid syndrome patients at week 24 and week 48.",[31],[42],"NOT_YET_RECRUITING","2024-09-03",{"date":76,"type":47},"2024-09-19",{"date":78,"type":20},"2024-10-15",{"date":80,"type":20},"2027-12-30",{"name":82,"class":54},"Peking University People's Hospital"]